ArticleOncoTargets and therapy2026
Efficacy and Safety of Low-Dose Hypofractionated Radiotherapy Combined with Immunotherapy for Liver Metastases: A Single-Center Retrospective Analysis.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of low-dose hypofractionated radiotherapy (LDHRT) for liver metastases when combined with immunotherapy. Methods: Patients with liver metastases receiving immunotherapy were enrolled in this study at Changzhou Second People's Hospital from January 2019 to May 2025 (Ethics Approval No. [2021]KY117-01). LDHRT (12 Gy in 3 fractions) was administered to the liver metastases using volumetric modulated arc therapy (VMAT). The tumor response was evaluated according to the RECIST 1.1 standard. Clinical and imaging data were collected to assess changes in tumors inside and outside the radiation field before and after LDHRT, as well as the median progression-free survival (PFS) for lesions within the radiation field. Results: A total of 51 patients were included, with the median age of 69 (range 47-84) years; 86.3% (44/51) were male, and 94.1% (48/51) had an ECOG performance status (PS) score ≥1. Additionally, 54.9% (28/51) had received ≥3 lines of prior therapy. Due to the continuous progression of liver metastases under systemic treatment, LDHRT was administered for the liver metastases. The study found a high local control rate within the radiation field as the objective response rate (ORR) and disease control rate (DCR) within the radiation field were 17.6% and 86.3%, respectively. However, the efficacy for lesions outside the radiation field was significantly inferior, with an ORR of 0% and a DCR of 35.3%. The median PFS for lesions within the radiation field was 4.23 months. Patients with colorectal liver metastases (CRLM) showed better PFS than those with gastric cancer liver metastases (GCLM). The most common adverse events were fatigue (16/51, 31.4%), abnormal liver function (11/51, 21.6%), and hypothyroidism (7/51, 13.7%). No patients discontinued treatment due to treatment-related adverse events. Conclusion: LDHRT combined with immunotherapy provided favorable local control and was generally well tolerated in patients with liver metastases. No apparent abscopal effect was observed, suggesting that single-lesion LDHRT was insufficient to reverse systemic immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.